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Recent evidence has suggested that mild depression of prothrombin activity
may encourage thrombus formation,’ and it has long been held that a similar
effect due to &dquo;rebound&dquo; hypercoagulability occurs after sudden withdrawal of
anticoagulant therapy. 2-5 This report assesses the effect of varying degrees of
prothrombin depression and abrupt correction of hypoprothrombinemia with
large doses of vitamin Kl on thrombus growth in vivo.
MATERIALS AND METHODS
Studies were performed on adult New Zealand white rabbits ranging in
weight from 3.5 to 6.0 kg and subsisting on Rockland Rabbit Ration. Warfarin
sodium in the form of Coumadin and vitamin Kl in the form of Aqua-Me-
phyton were utilized.
Thrombi were initiated in the ligated common carotid artery of the rabbit
by applying a direct current of 2.5 mamp for 30 min through platinum elec-
trodes (3 by 7 mm) placed central to the point of occlusion of the vessel.
Thrombi were removed and weighed after growth had been allowed to continue
for 6.5 hr in the obstructed vessel. Details of this method have been described
elsewhere.6 . ’ -
Prothrombin activity was measured by a one-stage technique’ utilizing
Acuplastin as the source of thromboplastin. Control curves were constructed
with pooled normal rabbit plasma, utilizing aluminum hydroxide adsorbed
rabbit plasma as the diluent.
EXPERIMENTS
Effect of u~ar f arin. Af ter base line prothrombin determination and measure-
ment of thrombus weight in one carotid artery, animals were injected with
warfarin at 2- to 3-day intervals to maintain prothrombin depression. Depend-
* This work was supported by a grant from the Michigan Heart Association.
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ing on the intensity of effect desired, and individual susceptibility, dosage
ranged from 13 to 20 mg per kg per week. Thirty animals were treated for
10 to 14 days and seven were treated for 30 days. These differences in duration
of therapy were chosen because Ashwin8 had observed greater inhibition of
thrombosis in rodents treated for 30 days than in those treated for a shorter
time. At the end of treatment, thrombosis was produced in the second carotid
artery, thrombus weight was obtained, and a final determination of prothrom-
bin activity was carried out.
Reversal of ’Lcarfarin effect with vitamin K, . Warf arin was administered
intramuscularly to 18 rabbits at 2- to 3-day intervals for 2 weeks (15 to 20 mg
per kg per week) and then each animal was injected with 50 mg of vitamin Kl .
Thrombus growth was measured in the first carotid artery 48 hr after Kl in
nine animals and 5 days after Kl in the other nine rabbits. The control throm-
bus was produced in the second carotid artery 7 days after the initial study in
both groups. Prothrombin time was determined before the first warfarin in-
jection, before Kl injection, and on the day of measurement of thrombus
growth in the first carotid artery.
’ 
RESULTS
Efj’ect of warfarin. Results were grouped according to prothrombin concen-
tration at the time of thrombogenesis in the second carotid artery and com-
pared to findings in a previously reported6 group of control animals. Since
TABLE 1*
Effect of warfarin on thrombus growth
* The influence of varying degrees of prothrombin depression on thrombus growth is
documented here. Of note is the lack of evidence for hypercoagulability in the >30 per cent
group.
t First and second carotid experiments separated by 7 to 36 days.
137
TABLE 2*
Effect of abrupt correction of decreased prothombin activity on thrombus growth
* After Kl administration, thrombi are not relatively heavier than in the control group.
If they were, then there would have been little difference between first and second carotid
thrombus weights in the Kl group.
t First and second carotid experiments separated by 24 hr. 
’
thrombi in any given prothrombin range were not smaller in those animals
treated for 30 rather than 10 to 14 days, all 37 treated animals were considered
together. As can be seen in table 1, thrombi in the second carotid artery of un-
treated animals were heavier than those in the first carotid (mean increase in
thrombus weight +23.9 per cent with first and second carotid studies separated
by 7 to 36 days). In treated animals with prothrombin concentrations in the
15 to 30 per cent or >30 per cent ranges, weights of second carotid thrombi
were also greater than first (+10.9 and +10.1 per cent, respectively). While
these changes were not as great as in untreated animals, the differences be-
tween controls and either treatment group were not statistically significant
(p > 0.1). In animals with prothrombin concentration < 15 per cent, however,
second carotid thrombi were significantly decreased in weight (mean change,
-20.3 per cent; p < 0.01).
Reversal of warfarin effect with vitamin Kl . Thrombus growth in the two
groups of rabbits treated with vitamin Kl was compared to that in control
animals. If a thrombophilic state were induced by Ki , thrombi in the first
carotid artery should have been relatively heavier than normal, thereby di-
minishing or obliterating the usual difference between second and first carotid
weights. As can be seen in table 2, results in both groups of Ki-treated animals
were the same as those observed in controls.* There was no suggestion of de-
crease in the mean per cent change in thrombus weight.
DISCUSSION
In our study of the effect of warfarin on thrombus growth the primary ob-
jective was to collect evidence bearing on the suggestion that &dquo;low dose&dquo; ther-
* Data presented here are based on findings in a group of normal rabbits with first and
second carotid thrombi produced on consecutive days. It is felt that this is a valid control
group since it has been demonstrated that second carotid thrombi average about 20 per cent
heavier regardless of the interval separating them from first thrombi (see reference 6, and
also table 1 in this paper).
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apy enhances thrombus formation. Accordingly, more animals were maintained
with minor prothrombin depression than in other groups. Yet, no evidence of
thrombophilia appeared under these circumstances. In addition we observed
no significant inhibition of thrombus growth in the group of rabbits with
prothrombin concentration in the accepted therapeutic range. A substantial
antithrombotic effect was apparent only in animals with prothrombin concen-
tration less than 15 per cent of normal. These results are consistent with those
obtained in previous similar investigations.8-!4 Coumarin therapy has been
found to inhibit thrombosis only when prothrombin levels are severely de-
pressed.
In none of the early studies with prothrombin-depressing agents was an ef-
fort made to collect data in animals with only mild disturbances of coagula-
tion. The work of Murphy and colleagues’ utilizing bifurcating plastic arterio-
venous shunts in pigs provided quantitative information bearing directly on
this area. In 22 animals treated with dicumarol for 8 to 14 days and with
prothrombin time 1 to 1.5 times normal the mean weight of thrombotic de-
posits was found to be significantly greater than that found in controls. In
discussing this finding the authors note that Ashwin8 had observed a similar
phenomenon in rats. On review of Ashwin’s data, however, this finding is not
impressive and has not been subjected to statistical evaluation. The reason for
the discrepancy between our findings and those of Murphy et al. is most likely
to be related to differences in methods for studying thrombosis. Specifically,
differences in (1) surface on which thrombi grow and (2) duration of growth
allowed deserve particular consideration. In shunt studies thrombi form on
inert surfaces and therefore any influence which living vessel wall might exert
on propagating thrombus is not measured. Rowsell’s observation’5 that adeno-
sine diphosphate-induced platelet aggregates in shunts do not break up whereas
intravascular aggregates do suggests that some property of vessel wall tends
to inhibit platelet accumulation. Therefore, mild increases in platelet adhe-
siveness, although detectable in shunts, might well be insignificant in arteries
due to the &dquo;protective action&dquo; of vessel wall.
Also, thrombi in extracorporeal shunts, particularly in the early stages of
their development, are composed mainly of platelets, and so it would not be
surprising that the weight of deposits formed during short periods of flow
(20 min) in such systems would be influenced primarily by the functional
status of circulating thrombocytes. In fact this seems to be true, since Murphy
has found the best in vitro correlation in his model to be with platelet adhe-
siveness. Our system on the other hand deals with thrombus growth over a
6Y2-hr period. The final weight of these thrombi is probably significantly in-
fluenced by nonplatelet factors. Also, for this reason, an increase in platelet
adhesiveness might be apparent in shunts, but lost in our model.
Anticoagulant therapy is commonly &dquo;tapered off&dquo; because of the clinical
impression that abrupt discontinuation of this treatment produces &dquo;rebound&dquo;
thrombosis. Support for this impression can be mustered from a number of
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clinical investigations,2-5 but unfortunately these are not controlled adequately
enough to allow definite conclusions. Approaching the clinical problem from
another point of view, however, Sise et al.ls found no evidence of rebound
after elective discontinuation of therapy, but they did discover such a tendency
in group of patients in whom treatment had been interrupted because of hemor-
rhage. Sevitt and Innes 17 reported an absence of increased venous thrombosis
at necropsy in patients who died shortly after discontinuation of prophylactic
anticoagulant therapy, and in some of these cases treatment had been termi-
nated because of bleeding. Recently Van Cleve 18 found no difference in the
frequency of thrombosis following abrupt as opposed to gradual cessation of
long term anticoagulant therapy in patients with myocardial infarction.
Laboratory evidence of hypercoagulability after stoppage of anticoagulant
therapy is scant. McGinty et al.l° noted a mild overcorrection of prothrombin
activity in the plasma of dogs recovering from the effects of dicumarol, and
Lang et a1.2° observed a slight shortening of the one-stage prothrombin time
in a small number of animals after discontinuation of a short acting anticoag-
ulant. This finding has not been reproduced in several human studies. 21-23
However, Poller and Thomson24 have reported a shortening of &dquo;cephalin time&dquo;
after withdrawal of chronic therapy in man.
If slight changes in certain coagulation tests do occur after stopping anti-
coagulants, their significance can be judged best by in vivo studies. Unfortu-
nately, only one such investigation had been carried out prior to the one re-
ported here. Moschos et a1.,24 utilizing Wessler’s technique of serum-induced
thrombosis, found no evidence of a thrombophilic state in rabbits 48 hr after a
standard hemorrhage, termination of warfarin injections, and administration
of 10 mg of vitamin K1 intravenously, but they did find a tendency toward
increased thrombosis 5 days after anticoagulant hemorrhage. The authors chose
the 5-day period because preliminary investigations had revealed that at this
point A. H. G. levels, which had been elevated during therapy, returned to
normal or subnormal, and because they postulate that decreased factor VIII
activity indicates hypercoagulability (and vice versa).
Our study in rabbits reveals no thrombophilia either at 48 hr or 5 days after
stopping warfarin and giving 50 mg of vitamin K1 intravenously. It is unlikely
that this result is due to our method being insensitive to increase in thrombotic
tendency, since we have been able to demonstrate a thrombophilic state after
bilateral carotid occlusions utilizing the same technique. Thrombosis may
occur after discontinuation of anticoagulant therapy due to persistence of
local or systemic factors predisposing to its occurrence. The available evidence,
however, indicates that it cannot be explained by the appearance of rebound
hypercoagulability or thrombophilia.
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